Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: A multivariate analysis

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1525-1533

  Garg, M B ^a,b   Lincz, L F ^a,b,c   Adler, K ^a   Scorgie, F E ^a,b   Ackland, S P ^a,b,c   Sakoff, J A ^a,b,c  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

5FU toxicity; colorectal cancer; pharmacokinetics; platelet lymphocyte ratio; telomere length

Indexed keywords

DIHYDROURACIL; FLUOROURACIL; FOLINIC ACID; URACIL;

ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD; BLOOD ANALYSIS; CANCER PATIENT; CHROMOSOMAL PARAMETERS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NEUTROPHIL COUNT; PATIENT CARE; PRIORITY JOURNAL; PYRIMIDINE METABOLISM; SEPSIS; TELOMERE LENGTH; THROMBOCYTE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TELOMERE;

EID: 84867901546     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.421     Document Type: Article

References (38)

1. Ackland SP, Garg MB, Dunstan RH (1997) Simultaneous determination of dihydroflurouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem 246: 79-85
2. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna-Thomé M, Flores-Estrada D, Diaz-Romero C, Rodríguez CM, Martínez L, Sánchez-Lara K (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10: 50
3. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC (1998) Progressive telomere shortening in aplastic anemia. Blood 91: 3582-3592
4. Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39: 91-100
5. Blackburn EH (2005) Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 579: 859-862
6. Chua W, Charles KA, Baracos VE, Clarke SJ (2011a) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104: 1288-1295
7. Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ (2011b) Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 79: 224-250
8. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28: 678-685
9. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51
10. Du H-Y, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, Wilson DB, Mason PJ, Bessler M (2009) TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 113: 309-316
11. Epel ES (2009) Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones 8: 7-22
12. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-2253
13. Frenck Jr RW, Blackburn EH, Shannon KM (1998) The rate of telomere sequence loss in human leukocytes varies with age. PNAS 95: 5607-5610
14. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17: 1105-1105
15. Gamelin E, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451
16. Garg MB, Sevester JC, Sakoff JA, Ackland SP (2002) Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B 774: 223-230
17. Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 57: 186-189
18. Gurney HP, Ackland SP, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using bodysurface area for dose calculation. J Clin Oncol 16: 2299-2304
19. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S, Pasini F, Ferrazzi E, Padrini R (2009) Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 100: 1549-1557
20. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with ageing. Nature 346: 866-868
21. Keefe DMK (2006) Mucositis management in patients with cancer. Support Cancer Ther 3: 154-157
22. Lincz LF, Scorgie FE, Sakoff JA, Fagan KA, Ackland SP, Enno A (2004) Telomere length predicts neutrophil recovery in the absence of G-CSF after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 34: 439-445
23. Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ (1991) In vivo loss of telomeric repeats with age in humans. Mutat Res 256: 45-48
24. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438
25. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F (1994) Relationship between fluorouracil systemic exposure and tumour response and patient survival. J Clin Oncol 12: 1291-1295
26. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3): 1215
27. Patel K, Anthoney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT (2004) Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15: 568-573
28. Rhyu MS (1995) Telomeres, Telomerase, and Immortality. J Natl Cancer Inst 87: 884-894
29. Rudolph KL, Chang S, Lee H-W, Blasco M, Gottlieb GJ, Greider C, DePinho RA (1999) Longevity, stress response, and cancer in aging telomerasedeficient mice. Cell 96: 701-712
30. Sakoff JA, De Waal E, Garg MB, Denham J, Scorgie FE, Enno A, Lincz LF, Ackland SP (2002) Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. Leuk Lymphoma 43: 2017-2020
31. Slagboom PE, Droog S, Boomsma DI (1994) Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 55: 866-869
32. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID (1982) Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 257: 8171-8176
33. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (The Mayo Clinic Regimen). Am J Clin Oncol 26: 103-106
34. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, van, Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, van Gennip AH (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. [Review] [72 refs]. Hum Genet 104: 1-9
35. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM (1994) Evidence for a mitotic clock in human hematopoietic stem-cells-loss of telomeric DNA with age. PNAS 91: 9857-9860
36. Vokes EE, Mick R, Kies MS, Dolan E, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14: 1663-1671
37. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, Testa NG (1998) Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 351: 178-181
38. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-L D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens R-M, Chefrour M, Favre R, Duffaund F, Seitz J-F, Zanaret M, Lacarelle B, Mercier C (2011) DPD-based adaptive dosing of 5FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 67: 49-56